[EN] HETEROARYL INHIBITORS OF PLASMA KALLIKREIN<br/>[FR] INHIBITEURS HÉTÉROARYLE DE LA KALLICRÉINE PLASMATIQUE
申请人:SHIRE HUMAN GENETIC THERAPIES
公开号:WO2022197758A1
公开(公告)日:2022-09-22
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
本发明提供了一种化合物及其组合物,可用作血浆卡利肌酶的抑制剂,并表现出相同的理想特性。
Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism
作者:Guiping Zhang、John D. McCorvy、Sida Shen、Jianjun Cheng、Bryan L. Roth、Alan P. Kozikowski
DOI:10.1016/j.ejmech.2019.111626
日期:2019.11
cyclopropane moieties were constructed through transition metal catalyzed [2 + 1]-cycloaddition of aromatic vinyl fluorides, and the absolute stereochemistry of the representative compound (-)-21a was established. Functional activity measuring calcium flux at 5-HT2 receptors reveals high potency for compounds (+)-21a-d. In particular, (+)-21b had no detectable 5-HT2B agonism and displayed reasonable selectivity